撤稿:化疗与多塔利单抗治疗晚期或复发性子宫内膜癌的成本效果
原文因作者发现计算质量调整生命年(QALY)的公式存在错误,导致数据与结论无效,作者主动联系期刊撤稿。原文未提供具体研究数据、方法学细节或临床结论。
要点
- 该文已应作者要求撤稿,原因是QALY计算公式错误使数据与结论无效。
- 原文未报告化疗与多塔利单抗成本效果的具体数值或比较结果。
- 撤稿声明未提供研究设计、样本量或临床推荐信息。
核心结论
- 该文已撤稿,因QALY计算公式错误导致数据及结论无效。
局限性
- 作者独立发现计算质量调整生命年(QALY)的公式存在错误,该错误使论文的数据和结论无效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal). This article has been retracted at the request of the Authors. The authors have independently identified an error in the formula that was utilized to calculate the Quality Adjusted Life Years which invalidates the data and the conclusion of the paper. The authors have contacted the journal requesting to retract the article. Apologies are offered to the readers of the journal for any confusion or inconvenience that may have resulted from the publication of this article.
引用
- Riedinger CJ, Barrington DA, Nagel CI, et al. RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer. Gynecol Oncol. 2024. PMID: 38554477. doi:10.1016/j.ygyno.2024.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。